



Interim Report Q4

Fourth quarter, October-December 2023

- SpheriCal® ESI was launched as commercially available
- Representatives of the Company participated in the second in-person consortium meeting for the NanoSHIELD project

Year to date, January-December 2023

- The Board of Directors resolved on a share issue, with subsequent approval by the EGM
- The Company raised approx. SEK 6,1 million* through a rights issue of shares
- The first instalment of the EDF grant was paid, amounting to approx. SEK 1,8 million**
- The Company exhibited and presented at the ASMS conference in Houston in June
- Progress within the NanoSHIELD project, funded by the European Defense Fund
- SpheriCal® prototypes were launched for beta testing for new applications beyond ESI

*before deduction of transaction related costs

**the grant is accrued and recognized as income continuously over a period of 18 months

Key Figures

(KSEK)	Fourth quarter		Full year	
	Oct-Dec 2023	Oct-Dec 2022	Jan-Dec 2023	Jan-Dec 2022
Net sales	190	1,101	1,601	2,912
Profit (loss) for the period	-1,311	-699	-4,831	-2,870
Total assets	9,055	8,483	9,055	8,483
Equity / assets ratio (%)	84	91	84	91
Cash flow for the period	-1,291	-803	2,484	-4,470
Basic earnings per share (SEK)	-0.12*	-0.10	-0.45*	-0.42

* adjusted for the shares issued in Q1 2023

COMMENTS FROM CEO ELIN MIGNÉRUS

During the end of 2023, the Company has expanded the SpheriCal® range of products to also include Electrospray Ionization (ESI) applications, building on the news of beta testing and pre-launch that were addressed previously during the year. We now have our eyes set on continuing to build on this momentum in 2024, both through further technological developments as well as in our commercial endeavors.

“There is an immense potential in a wide range of sectors, and we look forward to continuing the work”

Closing 2023, we look back at a year filled with exciting technological progress and interesting new and recurring customers, where the team has worked tirelessly to continue taking steps in the Company's journey.

Looking at the year 2023 as a whole, the Company has developed in many ways. In challenging market conditions, we have taken steps in strengthening the relationship with our customers, moving projects forward and exploiting new technologies. The launch of SpheriCal® ESI in Q4 2023 was a large milestone for the Company, and a goal set up for the year. This means that we can now offer our customers high-performing calibrants for several mass spectrometry applications, and we are also entering a larger market than previously covered. The new technology saw a great receipt at the American Society for Mass Spectrometry (ASMS) Conference in Houston in June, and we have had successful collaborations with beta testers of the product. We look forward to seeing the development of this new application in 2024, as we continue to push the technology out to the mass spectrometry market.

In 2023, we have also seen the development of the European Defence Fund (EDF) funded project Nano-SHIELD, which Polymer Factory takes part in together with international partners from five different European countries. This is an exciting opportunity to explore Polymer Factory's materials in a new application, where we can utilize the unique properties of our dendritic materials to contribute to the defence sector. There is an immense potential in a wide range of sectors, and we look forward to continuing the work in this project during the coming year.

During Q4, the Company communicated and update to the financial targets for the year, which is derived from several reasons; one being projects that were expected to move forward in late 2023 were pushed back in time. Although this has an impact on the Company's result for 2023, we look forward to



Elin Mignérus, CEO of Polymer Factory

continuing these projects in the new year and look forward to the development of our technology in our customers' applications.

2023 has also been Polymer Factory's first complete year as an ISO certified company. After receiving our certificate at the end of 2022, we are pleased to have built on this during the last year, both by improving our existing processes and continuing the development of our quality work. We have a robust system and a quality mindset at Polymer Factory, through which we have reached a maturity stage where we can collaborate with global life science companies that put huge importance on the quality and regulatory work.

Now in the beginning of a new year, Polymer Factory is looking forward to continuing our work together with collaborators, as well as executing on future stages of customer projects. We are ready to take on the work to move our company to the next stage, and we look forward to sharing this journey with all our customers, partners, and shareholders.

ELIN MIGNÉRUS
CEO

ABOUT POLYMER FACTORY

Polymer Factory is a leading developer and provider of dendritic nanomaterials, to be applied over a range of sectors globally.

Polymer Factory is in many ways an accelerator firm for dendritic nanotechnology – generating cutting-edge products desired by customers across different high-demand sectors. From our roots in dendritic materials, we have developed SpheriCal®, a pioneering calibration technology for mass spectrometry (MS), and more recently, our latest addition, DNGs. Our broad portfolio, comprising more than 300 products, has attracted customers from BigPharma, MedTech, BioTech, as well as the chemical and other industries.

Stemming from many years of cutting-edge research, Polymer Factory was founded by a team of well-renowned scientists. This research has evolved into a business that provides products to billion-dollar industries.

MISSION

Transform dendritic nanomaterials to mature innovations that fulfill technologically demanding sectors.





VISION

Global generator of groundbreaking dendritic technologies that accelerate innovations in high performance material and life science sectors.

What makes dendritic materials so special, and in many ways superior, is their flawlessness, multifunctionality and dynamic structure. This makes them ideal for a vast number of applications in an array of industrial uses, from applications within pharmaceuticals and diagnostics as well as the chemistry and material industries. Polymer Factory's dendritic materials have a number of competitive advantages:

- Structural perfection (i.e. they are monodisperse and structurally flawless).
- High scalability and batch-to-batch consistency – an important feature across several high-end sectors e.g. therapeutic and diagnostic applications.
- High loading capacity, enabling the attachment of an exact and large number of drugs while decreasing the drug's toxicity when merged with the dendritic material.
- High level of optimization and flexibility, allowing users to achieve desired targeted complexation and product formulation.
- Biocompatibility and biodegradability; the dendritic carriers degrade under physiological conditions.

For more information about Polymer Factory Sweden AB and our products, visit <http://www.polymerfactory.com>



EVENTS DURING Q4 2023

KEY EVENTS DURING THE PERIOD

In November, representatives of the Company participated in the second in-person consortium meeting for the Nano-SHIELD project, financed by the European Defence Fund.

On December 13, the Company announced an update on financial targets for FY 2023.

On December 21, the Company announced the release of SpheriCal® calibrants within the segment of electrospray ionization mass spectrometry, ESI-MS. The ESI market size is estimated to be many times higher than the MALDI market, the latter for which the Company also commercially offers calibrants.

On December 29, the Company released an investor letter*, describing more about the Company's core technology.

*the letter was released in Swedish.

KEY EVENTS AFTER THE END OF THE PERIOD

After the end of the period, the Company has continued the development of SpheriCal® technologies as well as dendritic nanogels (DNG).

The Company has received new leads within pharma and biotech sectors, where there has been a request for dendritic polymers.

RELATED PARTY TRANSACTIONS

There is a consultancy agreement between the Company and SCEM Consulting AB, which is partly owned by Michael Malkoch, regarding services related to his role as CTO for the Company.

During Q4, a total of KSEK 96 has been invoiced under the agreement. During 2023, a total of KSEK 384 has been invoiced under the agreement.

RISKS AND UNCERTAINTY FACTORS

Polymer Factory is exposed to various types of risks, which can be categorized as related to business and operations, industry and market, intellectual property, and financial risks. During the fourth quarter, it is assessed that no significant changes has occurred in respect of risks and uncertainties.

More details on the Company's risks and uncertainties are described in the Annual Report that was published on April 5, 2023, which can be found on the company's website.

ORGANIZATION

As per December 31, 2023, the number of employees in the company was 4, in addition to above mentioned consultancy agreement.

SHARE

Polymer Factory Sweden AB (publ) is listed on Spotlight Stock Market since April 7, 2021 under ticker POLYMER.

Total number of shares amounts to 10,699,422.

Spotlight Stock Market is a secondary name of ATS Finans AB, a securities company under the supervision of the Swedish Financial Supervisory Authority. ATS Finans AB is a subsidiary of Spotlight Group AB, a company listed on Spotlight Stock Market. Spotlight Stock Market operates a so-called MTF platform.

ACCOUNTING PRINCIPLES

The interim report is prepared in accordance with the Swedish Annual Accounts Act and the standards of the Swedish Accounting Standards Board (BFNAR 2012:1) (K3). Accounting principles are unchanged compared with 2022.

This report has not been reviewed by the company's auditor.

OTHER INFORMATION

A warrant program for the CEO and other employees was established on the extra general meeting on 20 December 2021. More information on the program and terms can be found on the Company's website.

FINANCIAL OVERVIEW

REVENUES

Net sales for the fourth quarter amounted to KSEK 190 (1,101), a decrease with 82% compared to Q4 2022. Net sales for the full year amounted to KSEK 1,601 (2,912), a decrease with 45% compared to the full year 2022. The decrease for the period is related to differences in number of customized projects running over the period; timing of projects varies throughout a year for the Company.

During the quarter there was a decrease in inventories with KSEK -88 (-52), due to sales of stock products. For the full year, the inventory value has changed with KSEK -677 (1,013) due to sales of stock products.

Other revenue amounted to KSEK 302 (7) for the period, and KSEK 1,223 (20) for the full year, which is derived from work performed under the grant from EDF.

Out of the four segments (Dendrimers and dendrons, Hyperbranched materials, SpheriCal® and DNG), Dendrimers and Dendrons and SpheriCal® were predominant in Q4 and Dendrimers and Dendrons was predominant for the full year. North America has been the predominant market during the period, whereas Europe has been the predominant market for the full year.

OPERATING EXPENSES

Total operating expenses amounted to KSEK 1,721 (1,755) for Q4 and KSEK 6,984 (6,815) for the full year respectively. For the full year, approx. KSEK 194 is related to the new share issue taking place in Q1 2023.

RESULT

Result amounted to KSEK -1,311 (-699) for the fourth quarter, and KSEK -4,831 (-2,870) for the full year. For the full year, the result is affected by the differences in change in inventory, which resulted in KSEK -677 (1,013) for the full year 2023, and KSEK 194 can be derived from share issue related posts.

Earnings per share amounted to SEK -0.12* (-0.10) for the fourth quarter and SEK -0.45* (-0.42) for year 2023.




*adjusted for the shares issued in Q1 2023.

CASH FLOW AND FINANCIAL POSITION

Cash flow from operating activities for the period was KSEK -1,291 (-778) and KSEK -2,233 (-4,480) for year 2023.

Cash flow for the period was KSEK -1,291 (-803) and for the full year KSEK 2,484 (-4,470), the latter being attributable to the new share issue in Q1 2023. As per December 31, 2023, Cash and bank amounted to KSEK 4,639 and equity amounted to 7,581.

The Board of Directors today make the assessment that the company's current liquidity is set based on existing business plans, is sufficient to finance the company for the next 12 months.



INCOME STATEMENT IN SUMMARY

(KSEK)	OCT-DEC 2023	OCT-DEC 2022	JAN-DEC 2023	JAN-DEC 2022
Revenue				
Net sales	190	1,101	1,601	2,912
Change in inventories of products in progress, finished goods and work in progress	-88	-52	-677	1,013
Other revenue	302	7	1,223	20
Total revenue, inventory changes, etc.	404	1,056	2,147	3,945
Operating expenses				
Raw material	-51	-135	-210	-417
Other external expenses	-637	-655	-2,989	-2,810
Staff costs	-937	-850	-3,381	-3,187
Depreciation of assets	-92	-94	-369	-369
Other operating expenses	-4	-21	-35	-32
Total operating expenses	-1,721	-1,755	-6,984	-6,815
Operating profit/loss	-1,317	-699	-4,837	-2,870
Financial items				
Interest	6	0	6	0
Total financial items	6	0	6	0
Total after financial items	-1,311	-699	-4,831	-2,870
Profit/loss before taxes	-1,311	-699	-4,831	-2,870
Taxes				
Tax on profit/loss for the period	-	-	-	-
Profit/loss for the period	-1,311	-699	-4,831	-2,870

BALANCE SHEET

(KSEK)	31 DECEMBER 2023	31 DECEMBER 2022
ASSETS		
Fixed assets		
Intangible fixed assets	700	817
Tangible fixed assets	1,932	2,185
Total fixed assets	2,632	3,002
Current assets		
Inventory	1,362	2,039
Current receivables	422	1,287
Cash and bank	4,639	2,155
Total current assets	6,423	5,481
TOTAL ASSETS	9,055	8,483
EQUITY AND LIABILITIES		
Equity		
Equity	12,412	10,566
Result of the period	-4,831	-2,870
Total equity	7,581	7,696
Liabilities		
Current liabilities	1,474	787
Total current liabilities	1,474	787
TOTAL EQUITY AND LIABILITIES	9,055	8,483

CASH FLOW STATEMENT

(KSEK)	OCT-DEC 2023	OCT-DEC 2022	JAN-DEC 2023	JAN-DEC 2022
Operating activities				
Cash flow from operating activities	-1,291	-778	-2,233	-4,480
Cash flow from operating activities	-1,291	-778	-2,233	-4,480
Investing activities				
Cash flow from investing activities	-	-25	-	-25
Cash flow from investing activities	-	-25	-	-25
Financing activities				
Cash flow from financing activities	-	-	4,717	35
Cash flow from financing activities	-	-	4,717	35
<i>Cash flow for the period</i>	<i>-1,291</i>	<i>-803</i>	<i>2,484</i>	<i>-4,470</i>
Bank				
Bank opening	5,930	2,958	2,155	6,625
Bank closing	4,639	2,155	4,639	2,155

CHANGES IN EQUITY

	SHARE CAPITAL	NON- REGISTERED SHARE CAPITAL	SHARE PREMIUM RESERVE	PROFIT BROUGHT FORWARD	PROFIT FOR THE PERIOD	TOTAL
2021-12-31	686	-	12,230	992	-3,378	10,530
New share issue	0		11			11
New warrant program			24			24
Disposition according to AGM				-3,378	3,378	0
Loss for the period					-2,870	-2,870
2022-12-31	686	-	12,265	-2,386	-2,870	7,695
New share issue	384		5,758			6,142
New share issue expenses			-1,425			-1,425
Disposition according to AGM				-2,870	2,870	0
Loss for the period					-4,831	-4,831
2023-12-31	1,070		16,598	-5,256	-4,831	7,581

The Board of Directors and the CEO assure that this interim report gives a true and fair view of the company's operations, position and results and describes significant risks and uncertainties that the company is facing.

This report has not been reviewed by the company's auditor.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16 February 2024.

Stockholm 2024-02-16
CEO, Elin Mignérus

COMPANY INFORMATION

Company name

Polymer Factory Sweden AB (PUBL)

Organizational number

556695-9531

Address

Teknikringen 48,
114 28 Stockholm, Sweden

Phone

+46 73-655 46 79

Website

www.polymerfactory.com

CALENDAR

Current financial year: 2024-01-01 – 2024-12-31

Annual Report FY2023: 2024-04-05

Interim Report (Q1): 2024-05-08

Annual General Meeting: 2024-06-05

Half-year Report (Q2): 2024-08-16

Interim Report (Q3): 2024-11-08

End-year Report (Q4): 2025-02-17

CONTACT

CEO


Elin Mignérus


E-mail

elin.mignerus@polymerfactory.com

Phone

+46 79-300 27 76



POLYMER 
FACTORY

WWW.POLYMERFACTORY.COM